How 4-Pro-MET Was Discovered: From Synthesis to Market

4-Pro-MET didn't start in 2025. Its roots go back to the 1970s, when Alexander Shulgin synthesized 4-HO-MET – the active compound 4-Pro-MET converts into. What happened next was straightforward pharmaceutical logic: take a known target, apply ester prodrug design, get a new compound with better stability. This article traces that lineage from Shulgin's lab through the rise of ester prodrug tryptamines to 4-Pro-MET's arrival as a novel research chemical.

Alexander Shulgin (1925-2014) made 4-HO-MET (4-Hydroxy-N-methyl-N-ethyltryptamine, metocin) in the 1970s while systematically mapping tryptamine structure-activity relationships. It became entry #21 in TiHKAL (1997). His own notes at 10-20 mg oral: "Qualitatively a lot like psilocin" – wave-like effects, altered perception of color and form. The synthesis used a two-step approach from 4-acetoxyindole via the Speeter-Anthony tryptamine synthesis.

4-HO-MET surfaced as a designer substance around 2008. By 2012 it was one of Europe's most popular research chemical tryptamines – clear headspace, strong visuals, low body load. But two problems grew. The 4-hydroxy group oxidizes fast, making it unstable. And legal walls closed in: NpSG scheduling in Germany from July 2019. The market needed something more stable and still available. That gap created the opening.

Ester prodrugs of 4-hydroxy tryptamines go back to the 1960s, with psilocybin itself as the natural prototype (phosphoryloxy ester). The synthetic acetyloxy (4-AcO) series – including 4-AcO-DMT and 4-AcO-MET – gained popularity in the 2000s-2010s for their improved stability over free-hydroxyl compounds. When 4-AcO-DMT was added to BtMG Anlage I in Germany in 2022, pressure to develop alternative ester variants intensified.

The propionyloxy (4-PrO) series is the next logical step: extending the acyl chain from two carbons (acetyloxy) to three carbons (propionyloxy). This provides marginally increased stability, slightly slower hydrolysis (potentially smoothing onset), and – critically – a different structure that falls outside existing scheduling definitions. 4-Pro-MET first appeared in vendor catalogs in August/September 2025, quickly gaining attention as a legal, stable prodrug of 4-HO-MET.

4-Pro-MET was first registered as a novel designer drug in August/September 2025. Its rapid adoption reflected several converging factors: the scheduling of 4-AcO-DMT (2022), NpSG coverage of 4-HO-MET (2019), strong community demand for MET-series compounds, and proven commercial viability of the prodrug tryptamine market. Within months, multiple European vendors were offering 4-Pro-MET in pellet and drop formats, with Certificates of Analysis confirming identity and purity.

The compound's molecular formula (C₁₆H₂₂N₂O₂, MW 274.364 g/mol) and its availability as a fumarate salt for stability were quickly documented. PubChem assigned CID 169222171. No academic publications addressing 4-Pro-MET have appeared as of April 2026, making community reports and structural analogy the only information sources available.